A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma

• Published in: Communications biology Vol. 4; no. 1; p. 383
• Main Authors: Mei, Ying, Chen, Mei-Ju May, Liang, Han, Ma, Li
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 22.03.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 38; 38/23; 38/39; 38/91; 45; 631/114/2397; 631/67/1059/2325; Biology; Biomarkers; Biomedical and Life Sciences; CTLA-4 protein; Gene set enrichment analysis; Genomes; Immune response; Life Sciences; Medical prognosis; Melanoma; Prognosis; Risk assessment; Skin cancer; Survival
• ISSN: 2399-3642; 2399-3642
• DOI: 10.1038/s42003-021-01911-x

Cutaneous melanoma is the most malignant skin cancer. Biomarkers for stratifying patients at initial diagnosis and informing clinical decisions are highly sought after. Here we classified melanoma patients into three immune subtypes by single-sample gene-set enrichment analysis. We further identified a four-gene tumor immune-relevant (TIR) signature that was significantly associated with the overall survival of melanoma patients in The Cancer Genome Atlas cohort and in an independent validation cohort. Moreover, when applied to melanoma patients treated with the CTLA4 antibody, ipilimumab, the TIR signature could predict the response to ipilimumab and the survival. Notably, the predictive power of the TIR signature was higher than that of other biomarkers. The genes in this signature, SEL1L3 , HAPLN3 , BST2 , and IFITM1 , may be functionally involved in melanoma progression and immune response. These findings suggest that this four-gene signature has potential use in prognosis, risk assessment, and prediction of anti-CTLA4 response in melanoma patients. Ying Mei et al. identify a four-gene tumor immune-relevant signature that predicts the overall survival of melanoma patients and their response to the CTLA4 antibody ipilimumab. This study suggests a potential utility of this four-gene signature in prognosis, risk assessment, and prediction of anti-CTLA4 response in melanoma patients.